Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Angelini Ventures said its portfolio company Noctrix Health was acquired by ResMed (NYSE: RMD) in a $340 million deal. Noctrix develops wearable, clinically validated neuromodulation therapies; its lead product Nidra is FDA-authorized for moderate-to-severe restless legs syndrome. Angelini Ventures invested in 2024’s $40 million Series C. The exit is described as its first.
Deal announcement is a direct growth/portfolio expansion for ResMed, potentially supporting future sleep/respiratory care revenue streams.
ResMed is the acquirer of Noctrix Health in a $340m transaction, with planned integration of Noctrix technology into its sleep ecosystem.
Moderately positive near-term bias as investors price in strategic expansion; magnitude depends on deal economics and guidance not provided here.
Background
Angelini Ventures (corporate VC) reports its first portfolio exit as ResMed acquires Noctrix Health; Noctrix’s lead product Nidra is described as the first FDA-authorized non-invasive therapy for moderate-to-severe Restless Legs Syndrome.
Why it matters
For ResMed, the acquisition is positioned as expanding its sleep health ecosystem via integration of neuromodulation wearable technology. For investors, the headline is a strategic M&A catalyst with a stated $340m valuation, but the article does not provide deal structure, expected synergies, or financial guidance.
Market relevance
A strategic acquisition in sleep health/connected care with a clear deal value can re-rate the acquirer’s growth narrative, though near-term trading will hinge on deal economics not included here.
Market effects
Supports the connected sleep/respiratory care medtech theme and validates neuromodulation wearables as investable assets.
Limited direct regional impact; transaction is global with Italian venture involvement.
Cross-border consolidation in sleep health medtech may spur follow-on interest in similar clinical-stage device platforms.
Alternative perspectives
Without disclosed revenue/EBITDA contribution or integration costs, the $340m price could be viewed as potentially dilutive or execution-risky.
Key sensitivities are (1) regulatory/clinical durability of Nidra, (2) reimbursement and adoption curve, and (3) whether integration accelerates ResMed’s addressable market versus cannibalizing existing offerings.
Key entities
- acquirerResMed
Buyer of Noctrix Health in a transaction valued at $340 million; plans to integrate Noctrix technology into its sleep health ecosystem.
- targetNoctrix Health
Medical technology company developing wearable, clinically validated neuromodulation therapies; lead product Nidra for Restless Legs Syndrome.
- seller/investorAngelini Ventures
Corporate venture firm that invested in Noctrix Health in 2024 and reports the exit as its first successful portfolio exit.
